arrow
N

Noelle V. Frey

university of pennsylvania
H指数:53
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Consensus Recommendations for CAR T Cell Administration in Adult Acute Lymphoblastic Leukemia: A Modified Delphi Study

成人急性淋巴细胞白血病CAR T细胞输注的共识建议:一项改良德尔菲研究

Blood
IF23.1
2026-05-220
PRE
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer

泛血液学癌症对嵌合抗原受体 (CAR) T细胞治疗反应的预测生物标志物

2026-03-090
PRE
Erratum to <[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>

勘误:《免疫效应细胞相关噬血细胞性淋巴组织细胞增多症样综合征》\[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9\]

2025-10-300
OAAI
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia

CAR HEMATOTOX 独立预测急性淋巴细胞白血病接受CD19 CAR-T疗法后的结局

2025-10-080
OAAI
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement

Brexucabtagene autoleucel在伴有CNS受累的复发/难治性急性淋巴细胞白血病患者中的疗效

2025-05-090
OAAI
Evolving racial/ethnic disparities in AML survival in the novel therapy era

新型疗法时代急性髓系白血病(AML)生存率的种族/族裔差异演变

2025-01-311
PRE
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
2024-12-102
OAAI
TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function
2024-11-150
OAAI
Real-World Outcomes of Early Relapsed/Refractory Large B Cell Lymphoma Patients Treated with 2 nd Line CAR T Therapy

真实世界中接受2线CAR T治疗早期复发/难治性大B细胞淋巴瘤患者的临床结局

BLOOD
IF23.1
2024-11-050
PRE
Cytokine-mediated CAR T therapy resistance in AML

细胞因子介导的AML car-t治疗耐药

2024-09-272
PRE
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

Blinatumomab治疗成人MRD阴性急性淋巴细胞白血病

2024-07-2511
PRE
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia
2024-04-181
OAAI
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients
2024-04-015
OAAI
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

商业CAR T细胞治疗后T细胞淋巴瘤和继发性原发性恶性肿瘤风险

2024-01-2481
PRE
Survival Outcomes for Patients with Relapsed/Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells
2023-08-014
OAAI